Logo image of PSH0.DE

SERNOVA BIOTHERAPEUTICS INC (PSH0.DE) Stock Fundamental Analysis

FRA:PSH0 - Deutsche Boerse Ag - CA81752F1062 - Common Stock - Currency: EUR

0.122  -0.01 (-10.29%)

Fundamental Rating

0

Taking everything into account, PSH0 scores 0 out of 10 in our fundamental rating. PSH0 was compared to 73 industry peers in the Biotechnology industry. Both the profitability and financial health of PSH0 have multiple concerns. PSH0 does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PSH0 had negative earnings in the past year.
PSH0 had a negative operating cash flow in the past year.
In the past 5 years PSH0 always reported negative net income.
In the past 5 years PSH0 always reported negative operating cash flow.
PSH0.DE Yearly Net Income VS EBIT VS OCF VS FCFPSH0.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

PSH0 has a Return On Assets of -914.25%. This is amonst the worse of the industry: PSH0 underperforms 90.41% of its industry peers.
Industry RankSector Rank
ROA -914.25%
ROE N/A
ROIC N/A
ROA(3y)-216.87%
ROA(5y)-153.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSH0.DE Yearly ROA, ROE, ROICPSH0.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PSH0 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSH0.DE Yearly Profit, Operating, Gross MarginsPSH0.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, PSH0 has more shares outstanding
Compared to 5 years ago, PSH0 has more shares outstanding
Compared to 1 year ago, PSH0 has a worse debt to assets ratio.
PSH0.DE Yearly Shares OutstandingPSH0.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
PSH0.DE Yearly Total Debt VS Total AssetsPSH0.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -104.71, we must say that PSH0 is in the distress zone and has some risk of bankruptcy.
PSH0's Altman-Z score of -104.71 is on the low side compared to the rest of the industry. PSH0 is outperformed by 89.04% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -104.71
ROIC/WACCN/A
WACCN/A
PSH0.DE Yearly LT Debt VS Equity VS FCFPSH0.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 0.10 indicates that PSH0 may have some problems paying its short term obligations.
PSH0 has a worse Current ratio (0.10) than 90.41% of its industry peers.
PSH0 has a Quick Ratio of 0.10. This is a bad value and indicates that PSH0 is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.10, PSH0 is doing worse than 90.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
PSH0.DE Yearly Current Assets VS Current LiabilitesPSH0.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 30.77% over the past year.
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.58% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.72%
EPS Next 2Y17.59%
EPS Next 3Y14.34%
EPS Next 5Y30.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PSH0.DE Yearly Revenue VS EstimatesPSH0.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
PSH0.DE Yearly EPS VS EstimatesPSH0.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.2 0.4 0.6 0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PSH0 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PSH0 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSH0.DE Price Earnings VS Forward Price EarningsPSH0.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSH0.DE Per share dataPSH0.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.01 -0.02 -0.03 -0.04 -0.05

4.3 Compensation for Growth

A more expensive valuation may be justified as PSH0's earnings are expected to grow with 14.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.59%
EPS Next 3Y14.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PSH0!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SERNOVA BIOTHERAPEUTICS INC

FRA:PSH0 (5/28/2025, 7:00:00 PM)

0.122

-0.01 (-10.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-03 2025-02-03/amc
Earnings (Next)N/A N/A
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners4.1%
Ins Owner ChangeN/A
Market Cap40.07M
Analysts80
Price Target1.6 (1211.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.65%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.33%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -914.25%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-216.87%
ROA(5y)-153.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z -104.71
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)32.35%
Cap/Depr(5y)110.01%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.79%
EPS Next Y60.72%
EPS Next 2Y17.59%
EPS Next 3Y14.34%
EPS Next 5Y30.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.27%
EBIT Next 3Y43.94%
EBIT Next 5Y22.63%
FCF growth 1Y-7.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.47%
OCF growth 3YN/A
OCF growth 5YN/A